These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27090177)

  • 1. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.
    Cai B; Cai Y; Liew YX; Chua NG; Teo JQ; Lim TP; Kurup A; Ee PL; Tan TT; Lee W; Kwa AL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4013-22. PubMed ID: 27090177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB).
    Cai Y; Chua NG; Lim TP; Teo JQ; Lee W; Kurup A; Koh TH; Tan TT; Kwa AL
    PLoS One; 2016; 11(7):e0158740. PubMed ID: 27441603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.
    Zusman O; Altunin S; Koppel F; Dishon Benattar Y; Gedik H; Paul M
    J Antimicrob Chemother; 2017 Jan; 72(1):29-39. PubMed ID: 27624572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Use of Polymyxin B.
    Rigatto MH; Falci DR; Zavascki AP
    Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
    Brown P; Dawson MJ
    J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
    Falagas ME; Rafailidis PI; Ioannidou E; Alexiou VG; Matthaiou DK; Karageorgopoulos DE; Kapaskelis A; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2010 Feb; 35(2):194-9. PubMed ID: 20006471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agents of Last Resort: Polymyxin Resistance.
    Kaye KS; Pogue JM; Tran TB; Nation RL; Li J
    Infect Dis Clin North Am; 2016 Jun; 30(2):391-414. PubMed ID: 27208765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection.
    Wang W; Jiang T; Zhang W; Li C; Chen J; Xiang D; Cao K; Qi LW; Li P; Zhu W; Chen W; Chen Y
    Am J Infect Control; 2017 Jan; 45(1):59-64. PubMed ID: 27765296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical analysis of sepsis with extensively drug resistant Gram-negative bacteria in intensive care unit treated with polymyxin B-based combination therapy].
    Zhao S; Yan L; Wang C; Peng M
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Feb; 32(2):150-154. PubMed ID: 32274997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
    Ting SW; Lee CH; Liu JW
    J Microbiol Immunol Infect; 2018 Oct; 51(5):621-628. PubMed ID: 28732563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Zavascki AP; Bulitta JB; Landersdorfer CB
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1333-53. PubMed ID: 24191943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
    Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
    Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement.
    ; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C
    Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis.
    Schmid A; Wolfensberger A; Nemeth J; Schreiber PW; Sax H; Kuster SP
    Sci Rep; 2019 Oct; 9(1):15290. PubMed ID: 31664064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.